Amgen files reply in support of quick appeal in CareFirst’s US case over Enbrel
MLex Summary: Amgen filed a reply supporting its petition to certify for immediate appeal CareFirst’s case accusing it of unlawfully delaying competition for its drug Enbrel after Amgen’s motion to dismiss...To view the full article, register now.
Already a subscriber? Click here to view full article